

Systematic Data Collection to Inform Policy Decisions:

Using the Laboratory Performance Database –
Region 4 Stork (R4S) MS/MS Data Project to
Improve Newborn Screening in Washington State



Ashleigh Fleischman, MPH

Washington State Department of Health

Washington Newborn Screening


- Screening panel determined by the State BOH
- Screen for 19 conditions using MSMS
 - FAP: VLCAD, MCAD, LCHAD, TFP, and CUD
 - AAP: PKU, CIT, ASA, HCY, MSUD, and TYR-I
 - OAP: PROP, Cbl A,B, MUT, IVA, BKT, HMG, MCD, and GA-I
- Use Multiple Reaction Monitoring (MRM) for limited number of analytes to reduce incidental findings



Informative Markers


Plot by Condition

VLCAD



Plot by Marker

C14:2



Informative Markers

Analyte	LCHAD				CUD	MCAD	MCAD	VLCAD	Ga-II	CACT/ CPT-II		CPT-I		
	CUD	/TFP	MCAD	VLCAD	(mat)	(het)	(mat)	(het)		CPT-I (P479L)	M/SCHAD	RED	SCAD	
H C10:1														
H C10														
H C3DC														
H C5DC														
H C12:1														
H C12														
H C14:2														
H C14:1														
H C14														
H C14-OH														
H C16:1														
L C16														
H C16														
L C18:2														
H C18:2														
L C18:1														
H C18:1														
L C18														
H C18														

Informative Markers

Analyte	LCHAD				CUD (mat)	MCAD (het)	MCAD (mat)	VLCAD (het)	Ga-III	CPT-I				
	CUD	/TFP	MCAD	VLCAD						CPT-II	CPT-I (P479L)	M/SCHAD	RED	SCAD
H C10:1			X						X					
H C10			x			x		x	x					
H C3DC			A											
H C5DC			X			X			X					
H C12:1				x				x	x					
H C12		A		A				A	A	A				
H C14:2		A		A				A	A					
H C14:1		X		X				X	X					
H C14		X		X				X	X	X				
H C14-OH		x		x				x	x	X				
H C16:1		x		x				x	x	X				
L C16	x				x						X			
H C16										X				
L C18:2											X	X		
H C18:2										X				
L C18:1	x				x						X			
H C18:1										X				
L C18	x				x						X			
H C18										X				


Informative Markers

- Added 9 new analytes
- Created 9 new ratios
- 12 of the 18 new markers are informative for a condition on our panel
- Impacted 9 conditions on our panel

Cutoff Review


Analyte Comparison

C14



Normal Percentile Comparison

WA





Score Card

C14

Normal Population (NP)							Target Range		Disease Range of True Positives (DR)									
Percentiles (µM) (Median of <i>N</i> lab %ile values)							NP 99%ile	DR 5%ile	Percentiles (µM) (Based on <i>N</i> values per analyte in reported cases)									
Analyte	<i>N</i>	1%	10%	50%	90%	99%	Not %ile Based		<i>N</i>	1%	5%	10%	25%	50%	75%	90%	99%	Condition
C14	110	0.070	0.13	0.22	0.35	0.50	0.50	0.80	125	0.13	0.27	0.37	0.74	1.44	2.36	3.85	7.39	GA-II
									70	0.24	0.40	0.48	0.73	1.24	1.67	2.92	4.81	CACT/CPT-II
									588	0.25	0.49	0.62	0.79	1.22	2.39	4.10	7.43	VLCAD
									175	0.31	0.46	0.50	0.61	0.71	0.84	1.00	1.46	VLCAD (het)
									212	0.15	0.22	0.27	0.41	0.63	1.03	1.45	2.67	LCHAD/TFP


Analyte Comparison



Post-Analytical Tools



All Condition tool




One Condition Tool

Cumulative Normal Percentile & VLCAD Disease Range Overlap Values							
Analyte	Normal	Overlap	Disease Range				Case Values
	99%ile		1%ile	5%ile	10%ile	50%ile	
C16	5.98	73.5 %	0.92	2.13	2.55	4.41	5.74
C2	51.39	97.9 %	7.18	10.31	12.40	21.69	7.13
	99%ile	%ile	1%ile	5%ile	10%ile	50%ile	Values
C14:1	0.35	0.0 %	0.57	0.71	0.85	1.74	3.31
C14:1/C16	0.12	0.0 %	0.14	0.18	0.21	0.40	0.58
C14:1/C2	0.02	0.2 %	0.02	0.03	0.03	0.08	0.46
C14	0.50	4.1 %	0.34	0.53	0.64	1.22	2.99
C14:2	0.08	5.9 %	0.05	0.07	0.10	0.23	0.34
C12:1	0.26	30.8 %	0.05	0.10	0.15	0.37	0.38
C14:1/C12:1	4.53	43.0 %	1.33	1.71	2.13	5.10	8.81


NP - DR Overlap

One Condition Tool



One Condition Tool

Case Score		
384 All	387 United States View Calculations	N/A Washington
%ile Rank of all VLCAD Scores:		
87 % All	86 % United States	N/A Washington
Count of VLCAD Scores		
261 All	145 United States	1 Washington
Score Interpretation Guidelines		
<p>This tool has been validated only for neonatal (<10 days) blood spots. Use of this tool is not advised to calculate scores for older patients.</p> <p>Score is ≥ 110 Condition is very likely VLCAD.</p> <p>Score is ≥ 50 and < 110 Condition is likely VLCAD.</p> <p>Score is ≥ 30 and < 50 Condition is possibly VLCAD.</p> <p>Score is < 30 Profile is not informative for VLCAD.</p>		



C3 R4S Tools			
Interpretation	Outcome (n)		PPV (%)
PROP Tool	PROP	NORM	
Very Likely	2	0	100
Possibly	0	4	
Not Informative	1	12	
Mut/Cbl A, B Tool	Mut/Cbl A, B	NORM	
Very Likely	5	8	39
Likely	0	7	
Possibly	0	1	
Cbl C, D Tool	Cbl C, D	NORM	
Very Likely	3	5	38
Likely	0	5	
Possibly	0	1	
Not Informative	0	2	
B12Def (mat) Tool	B12Def(mat)	NORM	
Very Likely	5	13	28
Likely	0	2	
Possibly	1	1	

C3 R4S Tools			
Interpretation	Outcome (n)		PPV (%)
PROP Tool	PROP	NORM	All Scores= 33
Very Likely	2	0	100
Possibly	0	4	
Not Informative	1	12	
Mut/Cbl A, B Tool	Mut/Cbl A, B	NORM	All Scores=24
Very Likely	5	8	39
Likely	0	7	
Possibly	0	1	
Cbl C, D Tool	Cbl C	NORM	All Scores=21
Very Likely	3	5	38
Likely	0	5	
Possibly	0	1	
Not Informative	0	2	
B12Def (mat) Tool	B12Def	NORM	All Scores=27
Very Likely	5	13	28
Likely	0	2	
Possibly	1	1	

C3 R4S Tools		
Interpretation	Outcome (n)	
All C3 Tools	True Positive	NORM
Very Likely	15	26
Possibly	0	14
Likely	1	7
Not Informative	1	14
PPV= 25%	Sensitivity = 94%	

Dual Scatterplots			
Interpretation	Outcome (n)		
VLCAD vs VLCAD (het) Tool	VLCAD	VLCAD(het)	NORM
VLCAD	1	0	0
VLCAD(het)	0	3	5
VLCAD or VLCAD (het)	1	10	1
None	0	0	2
MCAD vs MCAD(het)	MCAD	MCAD(het)	NORM
MCAD	3	0	0
MCAD(het)	0	0	1
PKU vs H-Phe	PKU	H-Phe	NORM
PKU	1	0	0
PKU or H-Phe	3	4	0

Thank You!!!



Washington NBS Program

- John D. Thompson, PhD, MPA, MPA
- Sheila Weiss, MS, CGC
- William Hoffman, BS
- Tim Davis, BS
- Mike Glass, MS

Biochemical Genetics Laboratory

- Piero Rinaldo, MD, PhD
- David McHugh

Questions?

ashleigh.fleischman@doh.wa.gov

(206) 418-5534

Washington State Newborn Screening

www.doh.wa.gov/nbs

(206) 418-5410

Come visit our lab!